Stock listing
BSE:MANKIND Mankind Pharma Ltd. Share Price
Indian listing (BSE) of Mankind Pharma Ltd. · home listing NSE:MANKIND
Follow Mankind Pharma Ltd. into a list and get an email when it puts out news.
Home listing price · NSE:MANKIND
₹2,665.00 INR +40.00 (+1.5%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NSE:MANKIND
- Day range
- ₹2,620.20 – ₹2,669.90 INRNov 20, 2026
- Volume
- 455,810 sharesNov 20, 2026
- Market cap
- ₹1.10T INRAt the close on Nov 20, 2026 · price × 413.0M shares outstanding
- 52-week range
- ₹1,909.70 – ₹2,705.00 INRLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- ₹1.36B INRMedian day 427,448 shares · 2 days with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NSE:MANKIND · Home | ₹2,665.00 INR | +40.00 (+1.5%) | 455,810 | ₹2,627.00 | ₹2,669.90 | ₹2,620.20 | ₹2,625.00 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NSE:MANKIND · INR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| ₹2,665.00 | +40.00 | +1.5% | ₹2,627.00 | ₹2,669.90 | ₹2,620.20 | 455,810 | |
| ₹2,625.00 | +15.00 | +0.6% | ₹2,619.90 | ₹2,645.50 | ₹2,607.10 | 341,826 | |
| ₹2,610.00 | -16.60 | -0.6% | ₹2,628.30 | ₹2,640.00 | ₹2,610.00 | 324,555 | |
| ₹2,626.60 | -13.40 | -0.5% | ₹2,625.60 | ₹2,694.00 | ₹2,612.20 | 426,990 | |
| ₹2,640.00 | +1.40 | +0.1% | ₹2,638.60 | ₹2,676.00 | ₹2,627.80 | 494,716 | |
| ₹2,638.60 | -21.40 | -0.8% | ₹2,660.00 | ₹2,667.90 | ₹2,631.20 | 424,048 | |
| ₹2,660.00 | -8.30 | -0.3% | ₹2,682.00 | ₹2,695.60 | ₹2,630.80 | 844,460 | |
| ₹2,668.30 | +128.30 | +5.1% | ₹2,600.00 | ₹2,705.00 | ₹2,585.20 | 1,515,775 | |
| ₹2,540.00 | +22.00 | +0.9% | ₹2,508.00 | ₹2,545.00 | ₹2,489.00 | 274,415 | |
| ₹2,518.00 | -19.90 | -0.8% | ₹2,560.00 | ₹2,561.20 | ₹2,495.00 | 377,284 | |
| ₹2,537.90 | +62.90 | +2.5% | ₹2,485.00 | ₹2,540.00 | ₹2,476.00 | 655,415 | |
| ₹2,475.00 | -6.20 | -0.2% | ₹2,500.00 | ₹2,500.00 | ₹2,461.10 | 770,945 | |
| ₹2,481.20 | -11.60 | -0.5% | ₹2,505.30 | ₹2,512.30 | ₹2,457.90 | 448,003 | |
| ₹2,492.80 | +23.50 | +1.0% | ₹2,469.30 | ₹2,528.00 | ₹2,467.40 | 681,380 | |
| ₹2,469.30 | -20.70 | -0.8% | ₹2,490.00 | ₹2,509.00 | ₹2,457.50 | 728,515 | |
| ₹2,490.00 | -12.50 | -0.5% | ₹2,496.60 | ₹2,549.00 | ₹2,477.40 | 1,085,402 | |
| ₹2,502.50 | +190.50 | +8.2% | ₹2,358.50 | ₹2,529.80 | ₹2,352.10 | 3,030,527 | |
| ₹2,312.00 | +99.40 | +4.5% | ₹2,223.70 | ₹2,333.90 | ₹2,215.00 | 1,024,537 | |
| ₹2,212.60 | -63.00 | -2.8% | ₹2,282.90 | ₹2,289.60 | ₹2,196.10 | 679,100 | |
| ₹2,275.60 | -9.90 | -0.4% | ₹2,266.00 | ₹2,299.60 | ₹2,233.60 | 649,740 | |
| ₹2,285.50 | +32.30 | +1.4% | ₹2,256.20 | ₹2,285.50 | ₹2,243.10 | 246,631 | |
| ₹2,253.20 | -22.30 | -1.0% | ₹2,264.10 | ₹2,348.50 | ₹2,246.00 | 1,228,705 | |
| ₹2,275.50 | -72.10 | -3.1% | ₹2,349.90 | ₹2,354.40 | ₹2,268.70 | 889,731 | |
| ₹2,347.60 | +12.60 | +0.5% | ₹2,325.60 | ₹2,365.00 | ₹2,321.10 | 645,492 | |
| ₹2,335.00 | -37.00 | -1.6% | ₹2,372.00 | ₹2,372.00 | ₹2,317.50 | 498,158 | |
| ₹2,372.00 | -28.00 | -1.2% | ₹2,400.00 | ₹2,401.10 | ₹2,356.20 | 329,114 | |
| ₹2,400.00 | +31.50 | +1.3% | ₹2,368.50 | ₹2,426.80 | ₹2,368.50 | 205,896 | |
| ₹2,368.50 | -11.50 | -0.5% | ₹2,380.00 | ₹2,389.80 | ₹2,342.00 | 306,899 | |
| ₹2,380.00 | -120.00 | -4.8% | ₹2,501.10 | ₹2,510.90 | ₹2,347.60 | 783,247 | |
| ₹2,500.00 | 0.00 | 0.0% | ₹2,500.90 | ₹2,530.00 | ₹2,480.10 | 242,210 | |
| ₹2,500.00 | +21.00 | +0.8% | ₹2,481.00 | ₹2,508.90 | ₹2,464.50 | 297,524 | |
| ₹2,479.00 | -56.00 | -2.2% | ₹2,533.10 | ₹2,539.30 | ₹2,464.70 | 527,032 | |
| ₹2,535.00 | 0.00 | 0.0% | ₹2,535.00 | ₹2,535.00 | ₹2,535.00 | 0 | |
| ₹2,535.00 | +31.20 | +1.2% | ₹2,500.00 | ₹2,535.00 | ₹2,476.10 | 427,905 | |
| ₹2,503.80 | -41.20 | -1.6% | ₹2,545.00 | ₹2,552.00 | ₹2,455.00 | 1,311,278 | |
| ₹2,545.00 | +109.40 | +4.5% | ₹2,436.80 | ₹2,559.00 | ₹2,436.80 | 1,973,968 | |
| ₹2,435.60 | -39.30 | -1.6% | ₹2,474.90 | ₹2,488.30 | ₹2,430.30 | 388,832 | |
| ₹2,474.90 | -25.10 | -1.0% | ₹2,488.30 | ₹2,504.60 | ₹2,454.40 | 333,769 | |
| ₹2,500.00 | +35.00 | +1.4% | ₹2,442.60 | ₹2,504.30 | ₹2,442.60 | 447,288 | |
| ₹2,465.00 | -15.00 | -0.6% | ₹2,475.10 | ₹2,493.00 | ₹2,458.10 | 352,575 | |
| ₹2,480.00 | +42.20 | +1.7% | ₹2,450.00 | ₹2,490.00 | ₹2,438.70 | 667,075 | |
| ₹2,437.80 | +137.10 | +6.0% | ₹2,312.70 | ₹2,452.00 | ₹2,303.00 | 1,342,757 | |
| ₹2,300.70 | +0.70 | 0.0% | ₹2,300.00 | ₹2,329.50 | ₹2,287.70 | 484,552 | |
| ₹2,300.00 | +54.00 | +2.4% | ₹2,252.70 | ₹2,308.80 | ₹2,242.10 | 488,064 | |
| ₹2,246.00 | -34.50 | -1.5% | ₹2,280.50 | ₹2,300.70 | ₹2,246.00 | 650,768 | |
| ₹2,280.50 | +0.50 | 0.0% | ₹2,280.00 | ₹2,300.90 | ₹2,251.80 | 446,450 | |
| ₹2,280.00 | 0.00 | 0.0% | ₹2,280.00 | ₹2,280.00 | ₹2,280.00 | 0 | |
| ₹2,280.00 | +41.60 | +1.9% | ₹2,237.20 | ₹2,280.00 | ₹2,222.00 | 530,698 | |
| ₹2,238.40 | -26.60 | -1.2% | ₹2,260.00 | ₹2,276.50 | ₹2,235.10 | 180,515 | |
| ₹2,265.00 | -44.00 | -1.9% | ₹2,305.00 | ₹2,317.60 | ₹2,250.00 | 266,219 | |
| ₹2,309.00 | -9.00 | -0.4% | ₹2,318.00 | ₹2,330.80 | ₹2,301.00 | 186,335 | |
| ₹2,318.00 | -9.90 | -0.4% | ₹2,317.00 | ₹2,331.60 | ₹2,303.50 | 153,500 | |
| ₹2,327.90 | -40.90 | -1.7% | ₹2,366.50 | ₹2,390.00 | ₹2,317.00 | 122,389 | |
| ₹2,368.80 | -22.70 | -0.9% | ₹2,390.00 | ₹2,390.00 | ₹2,355.40 | 98,805 | |
| ₹2,391.50 | +35.00 | +1.5% | ₹2,351.00 | ₹2,391.50 | ₹2,341.20 | 334,009 | |
| ₹2,356.50 | -62.70 | -2.6% | ₹2,381.40 | ₹2,381.40 | ₹2,350.00 | 282,979 | |
| ₹2,419.20 | +36.30 | +1.5% | ₹2,407.60 | ₹2,419.20 | ₹2,343.60 | 391,957 | |
| ₹2,382.90 | -34.60 | -1.4% | ₹2,419.00 | ₹2,422.10 | ₹2,370.00 | 190,737 | |
| ₹2,417.50 | +23.80 | +1.0% | ₹2,405.00 | ₹2,417.50 | ₹2,377.60 | 322,167 | |
| ₹2,393.70 | +28.70 | +1.2% | ₹2,358.00 | ₹2,423.90 | ₹2,358.00 | 513,001 | |
| ₹2,365.00 | -9.50 | -0.4% | ₹2,374.40 | ₹2,374.40 | ₹2,337.60 | 415,562 | |
| ₹2,374.50 | -9.50 | -0.4% | ₹2,385.00 | ₹2,385.10 | ₹2,367.10 | 130,471 | |
| ₹2,384.00 | -1.00 | 0.0% | ₹2,385.00 | ₹2,407.20 | ₹2,365.60 | 343,261 | |
| ₹2,385.00 | -9.00 | -0.4% | ₹2,413.00 | ₹2,413.00 | ₹2,373.40 | 307,625 |
- Ticker
- BSE:MANKIND
- Asset type
- Stock
- Sector
- Health care
- Industry
- Pharmaceuticals
- Exchange
- BSE
- Currency
- INR
What changed lately
Latest news release · Oct 26, 2026
Mankind Pharma Limited has informed the Exchange regarding a press release dated October 26, 2026, titled "Press Release on Financial Results for Q2 & H1 FY27".
Latest earnings call · Oct 26, 2026
Mankind Pharma (NSE:MANKIND) Q2 2027 Earnings Call
Replay and transcript
Latest deck · Oct 27, 2026
Investor Presentation (October 2026)
Investor deck · 27 slides
Latest news
Mankind Pharma Limited has informed the Exchange regarding a press release dated October 26, 2026, titled "Press Release on Financial Results for Q2 & H1 FY27".
Oct 26, 2026
Closed ₹2,312.00 (+4.5%) on Oct 26, 2026
Mankind Pharma Limited has informed the Exchange regarding a press release dated October 15, 2026, titled "Press Release titled Mankind Pharma to Acquire Majority Stake in Armed Cell Therapeutics, Marking Strategic Entry into Next-Generation CAR-T Therapies ".
Oct 15, 2026
Closed ₹2,275.50 (-3.1%) on Oct 16, 2026
Mankind Pharma Ltd. Press Release Aug 20 2026
Aug 20, 2026
Closed ₹2,385.00 (-0.4%) on Aug 20, 2026
Mankind Pharma Ltd. Press Release Jul 30 2026
Jul 30, 2026
Closed ₹2,575.90 (-0.6%) on Jul 30, 2026
Press Release May 19 2026
May 19, 2026
Closed ₹2,583.90 (+3.7%) on May 20, 2026
Press Release Mar 18 2026
Mar 18, 2026
Closed ₹2,000.80 (-4.9%) on Mar 19, 2026
Press Release Feb 03 2026
Feb 3, 2026
Closed ₹2,089.30 (-3.4%) on Feb 4, 2026
Actimed Therapeutics Announces Important Licensing Agreement with Mankind Pharma
Nov 21, 2025
Closed ₹2,242.10 (+0.1%) on Nov 21, 2025
Mankind Pharma Ltd. on 6ix
- Sector
- Health care
- Industry
- Pharmaceuticals
- News releases
- 7 in the last 12 months · 22 in all · newest Oct 26, 2026 · oldest 2023
- Calls
- 2 calls with a replay · 2 with a transcript · latest Oct 26, 2026
- Decks
- 32 decks · latest Oct 27, 2026
Where Mankind Pharma Ltd. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NSE:MANKIND · Home listing | NSE | India | INR |
| BSE:MANKIND · This page | BSE | India | INR |
Valuation
P/E 49.1× against a median of 32.9×: 8th lowest of 10 Pharmaceuticals companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- ₹1.13T INR
- P/E
- 49.1×
- EV/sales
- 7.3×
- EV/EBITDA
- 27.7×
- Price/book
- 6.3×
- Gross margin
- 58.7%
- Operating margin
- 20.6%
- Net margin
- 14.6%
- Debt to equity
- 0.3×
- Beta
- No index for this market yet
Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Mankind Pharma Ltd. · NSE:MANKIND | US$11.88B | US$12.18B | 49.1× | 7.3× | 27.7× | 6.3× | 14.6% | 0.3× | n/a |
| Ipsen SA · EURONEXT:IPN | US$14.62B | US$13.51B | 30.0× | 3.4× | 11.2× | 2.8× | 12.1% | 0.2× | n/a |
| Laurus Labs Ltd. · NSE:LAURUSLABS | US$13.38B | US$13.66B | 92.5× | 16.2× | 53.2× | 20.5× | 17.1% | 0.4× | n/a |
| Zydus Lifesciences Limited · NSE:ZYDUSLIFE | US$12.92B | US$13.86B | 28.6× | 4.2× | 17.9× | 4.3× | 13.8% | 0.5× | n/a |
| Elanco Animal Health Incorporated · NYSE:ELAN | US$12.87B | US$15.85B | n/a | 3.1× | 13.1× | 1.9× | −2.9% | 0.5× | 1.20 |
| Dr. Reddy's Laboratories Ltd. · NSE:DRREDDY | US$12.50B | US$12.45B | 41.4× | 3.5× | 22.6× | 3.0× | 8.5% | 0.2× | n/a |
| Cipla Ltd · NSE:CIPLA | US$12.34B | US$11.26B | 39.5× | 3.7× | 21.6× | 3.2× | 10.4% | 0.0× | n/a |
| Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. Class A · SSE:600436 | US$11.62B | US$11.29B | 58.9× | 9.5× | n/a | 5.5× | 16.7% | 0.0× | n/a |
| Aurobindo Pharma Ltd · NSE:AUROPHARMA | US$11.17B | US$11.02B | 25.9× | 2.8× | 13.4× | 2.6× | 10.8% | 0.2× | n/a |
| Lupin Limited · NSE:LUPIN | US$9.94B | US$9.65B | 17.7× | 2.9× | 10.1× | 3.8× | 17.0% | 0.2× | n/a |
| Sichuan Kelun Pharmaceutical Co., Ltd. Class A · SZSE:002422 | US$9.70B | US$8.05B | 32.9× | 2.9× | n/a | 2.5× | 10.7% | 0.0× | n/a |
| Median of the others | US$12.42B | US$11.87B | 32.9× | 3.4× | 15.6× | 3.1× | 11.5% | 0.2× | 1.20 |
Forecasts
Analysts' consensus from EODHD, read Nov 9, 2026. Not 6ix's view and not investment advice.
- Price target
- 2703.26 INR · Analysts' mean
- EPS, year to Mar 2027
- 58.88 · 17 analysts
- Revenue, year to Mar 2027
- 163.1B · 19 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Sheetal Arora | CEO & Whole-Time Director |
| Arjun Juneja | Chief Operating Officer |
| PK Arora | Director - FHA |
| Rajeev Juneja | Vice Chairman & Managing Director |
| Ramesh Juneja | Executive Chairman |
Board
| Director | Role |
|---|---|
| Ramesh Juneja | Executive Chairman |
| Anish Vanraj Bafna | Independent Director |
| Satish Kumar Sharma | Whole-Time Director |
| Sheetal Arora | CEO & Whole-Time Director |
| Tilokchand Punamchand Ostwal | Independent Director |
| Vijaya Sampath | Independent Director |
| Vivek Kalra | Independent Director |
Events
- Next results
- Jan 26, 2027 (expected)
Calls
| Call | When | Status |
|---|---|---|
| Mankind Pharma (NSE:MANKIND) Q2 2027 Earnings Call | Mon, Oct 26, 2026 · 10:10 AM ET | Replay |
| Mankind Pharma (NSE:MANKIND) Q1 2027 Earnings Call | Thu, Jul 30, 2026 · 10:58 AM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q2 2027 | Oct 26, 2026 · Before open | +4.5% |
| Q1 2027 | Jul 30, 2026 · Before open | −0.7% |
| Q4 2026 | May 19, 2026 · Before open | −0.1% |
| Q3 2026 | Feb 3, 2026 · Before open | +4.8% |
| Q2 2026 | Nov 6, 2025 · Before open | −2.5% |
| Q4 2025 | May 21, 2025 · Before open | −0.7% |
| Q3 2025 | Jan 23, 2025 · Before open | +4.7% |
| Q2 2025 | Nov 5, 2024 · Before open | −0.6% |
| Q4 2024 | May 15, 2024 · Before open | −2.6% |
| Q3 2024 | Jan 31, 2024 · Before open | −2.6% |
All 12 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q2 2024 | Oct 31, 2023 · Before open | −0.6% |
| Q1 2024 | Aug 2, 2023 · Before open | −1.8% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (October 2026) | Investor deck | 27 slides | Oct 27, 2026 |
| Q2 FY27 Earnings Presentation | Earnings | 26 slides | Oct 26, 2026 |
| Q1 FY27 Earnings Presentation | Earnings | 24 slides | Jul 30, 2026 |
| Q4 FY26 Earnings Presentation | Earnings | 33 slides | May 19, 2026 |
| Q3 FY26 Earnings Presentation | Earnings | 31 slides | Feb 3, 2026 |
| Q3 FY26 Earnings Presentation | Earnings | 30 slides | February 2026 |
| Q2 FY26 Earnings Presentation | Earnings | 34 slides | Nov 6, 2025 |
| Q2 FY26 Earnings Presentation | Earnings | 33 slides | November 2025 |
| Q1 FY2026 Earnings Presentation | Earnings | 30 slides | Jul 31, 2025 |
| Q1 FY26 Earnings Presentation | Earnings | 29 slides | July 2025 |
All 32 decks
Financials
Annual, in INR
Income statement
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 142.8B | 122.1B | 102.6B | 87.5B | 77.8B | 62.1B | 58.7B | 49.8B |
| Cost of revenue | 81.2B | 35.7B | 32.6B | 29.6B | 24.7B | 18.2B | 4.55B | 17.5B |
| Gross profit | 61.6B | 86.4B | 70.0B | 57.9B | 53.1B | 43.9B | 54.1B | 32.3B |
| Research and development | 2.32B | 254.5M | 254.5M | 20.4M | 123.7M | 1.10B | ||
| Selling, general and administrative | 15.0B | 27.2B | 23.0B | 11.0B | 1.25B | 748.8M | 529.7M | 11.1B |
| Operating income | 27.3B | 25.2B | 22.4B | 16.4B | 18.8B | 16.1B | 14.7B | 16.5B |
| Depreciation and amortization | 8.86B | 6.21B | 3.98B | 3.26B | 1.67B | 1.19B | 990.6M | 661.7M |
| EBITDA | 36.2B | 31.4B | 26.4B | 19.7B | 20.5B | 17.3B | 15.7B | 17.1B |
| Interest expense | 6.39B | 4.08B | 278.2M | 419.9M | 202.3M | 177.2M | 156.4M | |
| Income before tax | 23.3B | 25.2B | 24.0B | 16.7B | 19.7B | 16.9B | 14.4B | 8.75B |
| Income tax | 3.95B | 5.10B | 4.57B | 3.62B | 5.22B | 3.99B | 3.82B | 2.64B |
| Net income | 19.1B | 19.9B | 19.1B | 12.8B | 14.3B | 12.7B | 10.3B | 5.79B |
| Earnings per share, basic | 46.28 | 49.20 | 47.68 | 32.00 | 35.78 | 31.59 | 25.72 | 14.44 |
Balance sheet
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 4.83B | 5.54B | 3.82B | 3.05B | 3.03B | 1.67B | 2.26B | 1.16B |
| Short-term investments | 15.4B | 16.9B | 30.0B | 12.2B | 9.77B | 18.4B | 8.58B | 246.2M |
| Receivables | 17.3B | 15.4B | 8.48B | 6.06B | 4.27B | 4.24B | 6.26B | 2.20B |
| Inventory | 21.4B | 20.9B | 15.5B | 15.0B | 17.6B | 11.8B | 8.99B | 8.21B |
| Current assets | 69.5B | 69.9B | 65.7B | 43.3B | 44.1B | 39.1B | 28.2B | 20.0B |
| Goodwill | 64.9B | 64.9B | 200.2M | 200.2M | 204.4M | 204.4M | 204.4M | 204.5M |
| Total assets | 280.8B | 277.6B | 119.6B | 97.2B | 91.5B | 63.7B | 50.7B | 41.1B |
| Accounts payable | 13.4B | 11.3B | 11.0B | 7.77B | 10.8B | 6.67B | 7.45B | 5.62B |
| Current liabilities | 65.1B | 56.6B | 21.2B | 18.6B | 26.2B | 13.5B | 12.6B | 10.2B |
| Long-term debt | 28.2B | 55.3B | 248.7M | 231.5M | 491.9M | 576.7M | 503.4M | |
| Total debt | 63.1B | 85.1B | 2.07B | 1.70B | 8.73B | 2.41B | 1.28B | 2.70B |
| Total liabilities | 115.2B | 131.9B | 23.9B | 20.7B | 28.3B | 15.1B | 14.0B | 11.3B |
| Shareholders' equity | 163.0B | 143.3B | 93.6B | 74.4B | 61.6B | 47.2B | 34.9B | 28.2B |
| Shares outstanding | 413.3M | 404.7M | 401.2M | 400.6M | 400.6M | 400.6M | 400.6M | 400.6M |
Cash flow
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 25.2B | 24.1B | 21.5B | 18.1B | 9.20B | 11.4B | 10.7B | 6.00B |
| Capital spending | -6.26B | -4.61B | -3.82B | -8.32B | -23.5B | -3.12B | -2.28B | -2.98B |
| Free cash flow | 18.9B | 19.5B | 17.7B | 9.53B | -14.3B | 8.25B | 8.42B | 3.03B |
| Cash from investing | -2.54B | -126.9B | -20.8B | -10.5B | -13.7B | -12.2B | -4.39B | -4.44B |
| Cash from financing | -22.9B | 102.3B | 52.7M | -7.40B | 6.05B | -78.1M | -5.31B | -2.28B |
| Dividends paid | -412.7M | -3.64B | -240.4M | |||||
| Change in cash | 754.1M | 218.7M | 771.9M | 217.6M | 1.56B | -924.0M | 1.03B | -719.9M |
Filings
All 21 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| Press Release Jan 23 2025 | Jan 23, 2025 | Results | NSE India |
| Press Release Nov 05 2024 | Nov 5, 2024 | Results | NSE India |
| Press Release Oct 23 2024 | Oct 23, 2024 | Acquisition or disposal | NSE India |
| Press Release Jul 31 2024 | Jul 31, 2024 | Other filings | NSE India |
| Press Release Jul 25 2024 | Jul 25, 2024 | Acquisition or disposal | NSE India |
| Press Release May 15 2024 | May 15, 2024 | Results | NSE India |
| Press Release Mar 11 2024 | Mar 11, 2024 | Other filings | NSE India |
| Press Release Jan 31 2024 | Jan 31, 2024 | Results | NSE India |
| Press Release Oct 31 2023 | Oct 31, 2023 | Other filings | NSE India |
| Press Release Aug 02 2023 | Aug 2, 2023 | Results | NSE India |
| Press Release May 30 2023 | May 30, 2023 | Results | NSE India |
Cap table
Built by 6ix from Mankind Pharma Ltd.’s releases
- Common shares
- 413,045,090
- Fully diluted
- 413,045,090
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 413,045,090 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 413,045,090 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Anish Vanraj Bafna | Independent Director · Since at least Nov 6, 2026 |
| Arjun Juneja | Chief Operating Officer · Since at least Nov 6, 2026 |
| PK Arora | Director - FHA · Since at least Nov 6, 2026 |
| Rajeev Juneja | Vice Chairman & Managing Director · Since at least Nov 4, 2026 |
| Ramesh Juneja | Executive Chairman · Since at least Nov 4, 2026 |
| Satish Kumar Sharma | Whole-Time Director · Since at least Nov 6, 2026 |
| Sheetal Arora | CEO & Whole-Time Director · Since at least Nov 4, 2026 |
| Tilokchand Punamchand Ostwal | Independent Director · Since at least Nov 6, 2026 |
| Vijaya Sampath | Independent Director · Since at least Nov 6, 2026 |
| Vivek Kalra | Independent Director · Since at least Nov 6, 2026 |
Log in to ask 6ix AI your own questions about Mankind Pharma Ltd.